Fingerprint
Dive into the research topics of 'A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically